• Cautious market climate hampers sales growth • Positive adjusted EBITDA and cash flow • We keep o...
Redeye provides a research update following the Q1 report recently published by Isofol.
We upgrade FLU to BUY. The shares have delivered nearly no return since our June 2023 Hold initiatio...
MAX published its Q1 2026 figures. These showcased a resilient performance in challenging market env...
Redeye comments on the licensing deal with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA.
Redeye returns with a research update on Sprint Bioscience following the Q1 report.
Redeye provides its initial take on Lagercrantz’s Q4 2025/2026 report, which beat our sales and EBIT...
Kentimas Q1-rapport var svagare än väntat med låg omsättningstillväxt och pressad lönsamhet till föl...
Redeye initiates coverage of 4C Group, a Swedish defence software company specialising in military e...
Redeye provides an update following Acarix’s Q1 2026 report, which showed revenues in line with esti...
Gofore's April sales data was slightly behind our estimate.
Eurobattery Minerals ("Eurobattery") är ett prospekterings- och gruvutvecklingsbolag.
Active Biotechs ögonprojekt redovisade nyligen data från en biodistributionsstudie i ett litet antal...
Redeye provides its initial take on Acarix’s Q1 report, which saw sales in line with estimates but a...
IDL reported a record quarter with a high gross margin of 66%, driven by higher volumes.
Redeye notes that Smart Eye's Q1 2026 result was strong on almost all metrics, with the Automotive S...
Redeye comments on Oncopeptides’ Q1 report. Sales amounted to SEK25m, an increase by 37% versus Q4 2...
Siljansvik delivered a strong Q1’26 report with improved earnings across essentially all major holdi...
Redeye updates its estimates and valuation after Relais’ Q1 2026 report.
Ahead of Solwers' Q1 2026 report, we make minor estimates revisions for 2026-28.